Orforglipron Capsule
Activate GLP-1 receptors. Support metabolic balance.
Orforglipron is an investigational, once-daily oral GLP-1 receptor agonist studied for type 2 diabetes and chronic weight management in adults with obesity. This small-molecule, non-peptide agent mimics natural GLP-1 to regulate blood sugar, delay gastric emptying, and reduce appetite. Clinical trials demonstrate significant weight loss, with the highest dose in the ACHIEVE-1 trial yielding an average of 16.0 lbs (7.9%) loss at 36 weeks. Side effects are typically mild gastrointestinal events. This product is priced at the lowest strength of 12mg per capsule.
Pricing subject to change. Final dose and eligibility confirmed by a licensed clinician after intake.